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Clinical study of cardiac markers in post myocardial infarction patients on Antihypertensive  
drug therapy     
 
ABSTRACT 
Clinical study of Cardiac Markers in post myocardial Infarction Patients on 
Antihypertensive Drug Therapy 
Aim and objective:  
To assess the level of cardiac markers during anti-hypertensive drug 
therapy in post myocardial infarction patients. 
Materials and methods:  
A prospective – observational study was carried out in post myocardial 
infarction patients with history on antihypertensive therapy. Patient’s 
demographic details, previous medical history of MI and duration on 
antihypertensive treatment were collected and the effectiveness of 
antihypertensive drug therapy on cardiac workload was evaluated with the help of 
cardiac markers by using one way ANOVA followed by Tukey- Kramer multiple 
comparison test. Patient information leaflet was prepared and assessed.  
Results:  
The study result showed that Ramipril has a greater control on troponin – I 
and CK-MB profile of the patients (P< 0.01) when compared to Nicorandil. After 
Ramipril, Amlodipine showed a significant control (P< 0.05) when compared to 
Nicorandil on Troponin – I profile.  
Duration of antihypertensive drug treatment revealed that Ramipril 
decreases the incidence of second MI symptoms for longer duration than other 
drugs. 
Conclusion:  
  Our study revealed that Ramipril has significant control on troponin-I and 
CK-MB level in post MI While amlodipine showed a significant control only on 
troponin-I. 
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Duration of antihypertensive drug treatment among the study population 
revealed that Ramipril decreases the incidence of second MI symptoms for 
longer duration and decrease the release of cardiac markers compared to other 
drugs. It may due to decrease in workload of heart by ACE inhibitors. 
Patient information leaflet was prepared and distributed through cardiology 
department to improve patients understanding of disease management and the 
developed leaflet was found to be very useful by the patients.     
Keywords: Cardiac markers, myocardial infarction, Antihypertensive drugs.  
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1. INTRODUCTION 
1.1 Myocardial Infarction:  
 The third universal definition of myocardial infarction is defined as 
myocardial necrosis in clinical setting consistent with myocardial ischemia. These 
conditions can be satisfied by a rise of cardiac biomarker values (preferably 
cardiac troponin cTn) above the 99th percentile upper reference limit with atleast 
one of the following: 
 Symptoms suggestive of ischemia. 
 ECG changes indicative of new ischemia (significant ST- segment/T- wave 
changes or left bundle branch block LBBB). 
 Development of pathological Q – waves in the ECG. 
 Imaging evidence of new loss of viable myocardium or regional wall motion 
abnormality. 
 Detection of an intracoronary thrombus by angiography or autopsy.`1 
1.2 Classification of myocardial infarction: 
 Based on ECG findings, MI is classified into ST elevated MI (STEMI), 
NON-ST elevated MI (NSTEMI), Q wave MI and NON-Q MI. 
Based on pathological, clinical and prognostic differences along with 
different treatment strategies, they are broadly classified into 5 types: 
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A). Spontaneous myocardial infarction: 
 It is referred as atherosclerotic plaque rupture, ulceration, fissuring, 
erosion or dissection with resulting intraluminal thrombus in one or more of the 
coronary arteries which lead to decreased myocardial blood flow or distal platelet 
emboli with myocyte necrosis. The patient may have severe CAD/non-
obstructive/no CAD. 
B). Myocardial infarction secondary to ischemic imbalance: 
 It is defined as an imbalance between myocardial oxygen supply and or 
demand in condition other than CAD, for e.g Coronary endothelial dysfunction, 
coronary artery spasm, coronary embolism, tachycardia, bradycardia, 
arrhythmias, anemia, respiratory failure, hypotension and hypertension with or 
without LVH.   
C). Myocardial infarction resulting in death when biomarker values are 
unavailable: 
 It refers to Cardiac death with symptoms suggestive of myocardial 
ischemia and presumed new ischemic changes in ECG or new LBBB but death 
occurs before blood samples could be obtained or before cardiac biomarker 
could raise or not collected. 
D) 1. Myocardial infarction related to Percutaneous coronary intervention: 
 It is defined by elevated cardiac troponin values >5 with 99/ ≤ 99 percentile 
URL or a rise of cardiac troponin values >20% with elevated or stable or falling 
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baseline values. In addition with either symptoms of myocardial ischemia, ECG 
changes or new LBBB, loss of function of major coronary artery, new loss of 
viable myocardium or wall motion abnormality. 
D) 2. Myocardial infarction related to stent thrombosis:   
 It is detected by either coronary angiography or autopsy in myocardial 
ischemia with a rise and/or fall of cardiac biomarkers values with atleast one 
above the 99th percentile URL. 
E). Myocardial infarction related to coronary artery bypass grafting (CABG): 
 It is defined by elevation of cardiac biomarker values >10 with normal (99 
percentile URL). In addition with either new Q waves/LBBB or new graft or 
coronary artery occlusion or imaging evidence of new loss of viable myocardium 
or wall motion abnormality. 2 
1.3 Epidemiology: 
 Cardiovascular disease is considered as one important priority in 
healthcare system worldwide and burden of these cardiovascular diseases is 
increasing in low, moderate and high income countries. In worldwide, mortality 
rate due to these diseases is 265 per 100,000 populations. In 2015, about 15.9 
million people had MI in worldwide and 3million people had a STEMI. 
  By 2020, it is estimated that cardiovascular disease mortalities will 
increase by 15% in developed countries.3, 4 
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1.4 Pathophysiology: 
Due to sudden disruption of an atheromatous plague, platelets adhere and 
become activated. It releases potent secondary aggregators like (thromboxane 
A2, adenosine diphosphate and serotonin). Other mediators activate the extrinsic 
pathway of coagulation, vasospasm (platelet aggregation and mediator release, 
within minutes the thrombus can evolve to completely occlude the coronary 
lumen of the coronary vessel. If it’s partial known as NSTEMI and totally 
occlusive coronary vessel is known as STEMI. It leads to myocardial ischemia 
and necrosis. 
Figure: 1 Pathophysiology of myocardial infarction 
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1.5 Etiology:  
 Atherosclerosis 
 Age, Gender 
 Family history 
 Hypercholesterolemia 
 Dyslipidemia 
 Diabetes mellitus, hypertension 
 Stress, obesity 
 Sedentary life style 
 Reduced consumption of fruits and vegetables 
 Drug use 
 Coronary occlusion secondary to vasculitis etc.5 
1.6 Signs and Symptoms: 
 Chest pain 
 Radiation of  chest pain to jaw, teeth, shoulder, arm and or back 
 Dyspnea, shortness of breath 
 Epigastric discomfort with or without nausea or vomiting 
 Diaphoresis or sweating 
 Syncope with or without other cause 
 Impairment of cognitive function without other cause. 
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1.7 Diagnosis: 
 ECG 
 Echocardiogram 
 Chest x-ray 
 Coronary catheterization (angiogram) 
 Exercise stress test 
 Blood test 
 Cardiac computerized tomography (CT)  
 Magnetic Resonance Imaging (MRI) 
 Cardiac markers such as CK, CK-MB, Troponin-I, Troponin-T. 
1.8 Treatment: 
Non Pharmacological treatment: 
 To advice people to eat Mediterranean style diet like more bread, fruits, 
vegetables, fish, less meat and to replace cheese and butter with products 
based on plant oils. 
 To advice people who drink alcohol to keep weekly consumption within 
safety limits (not more than 21 units of alcohol per week for men & 14 units 
for women).   
 To undertake regular physical activity. 
 To quit smoking. 
 Advice patient to maintain healthy weight. 
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Pharmacological treatment: 
1. Anti-platelet agents: Aspirin, Clopidogrel. 
2. Nitrates: Nitroglycerin 
3. Analgesics: Morphine sulfate 
4. β-blockers: Metoprolol, Atenolol, Carvedilol 
5. Anti-coagulants: unfractioned heparin, low molecular weight heparin like                         
Dalteparin and Enoxaparin. 
6. ACE inhibitors: captopril, Ramipril, Lisinopril, Enalapril. 
7. Glycoprotein IIb/IIIa inhibitors: Abciximab, Eptifibatide, Triofiban. 
8. Statins: Atorvastatin, Pravastatin. 
9. Aldosterone antagonist: Epleronone. 
     Other treatment options: 
 Percutaneous coronary intervention (PCI) 
 Surgical Revascularization (CABG) 
 Implantable cardiac defibrillators (ICDs).6 
1.9 Cardiac markers: 
 Cardiac markers are substances that are released into the blood stream due 
to injury to the cardiac muscle.  
It is used for the diagnosis of acute myocardial infarction or acute coronary 
syndrome due to myocardial damage. 
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1.10 Types of markers: 
 Cardiac troponin I and T 
 Creatine kinase (CK) 
 Creatine kinase – myoglobin (CK-MB) 
 hs – c – reactive protein (hs – CRP) 
 Myeloperoxidase (MPD) 
  Ischemic modified albumin (IMA) 
  B type natriuretic peptide (BNP). 
Cardiac troponin I and T:  
 Cardiac troponins are regulatory proteins that controls calcium mediated 
interaction between actin and myosin in cardiac muscle. They are more cardio 
specific than CK-MB.  
Hence they are used mainly to aid in the diagnosis of chest pain patients 
with non-diagnostic ECG and also used as prognostic indicators of a MI and to 
identify patients having an increased risk from cardiac events resulting in death. 
Troponin level begins to raise in 3 – 4 hours after the onset of ACS and 
roughly 80% of patients with ACS will have positive value at 3 hours. These 
levels remain elevated for 7 to 10 days. Normal range: <0.07mg/ml or <5mIU/ml. 
Creatine kinase: (CK) 
 Ck is an enzyme which is present in high concentration in heart muscle, 
skeletal muscle, Brain and in other tissues. Levels are markedly increased in 
myocardial infarction, shock, circulatory failure and in muscular dystrophies. 
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CK begins to rise at 4 – 6 hour after MI, peak at 24 hours and return to 
normal within 48 to 72 hours.  
Normal range: 25 – 200 U/L.  
Creatine kinase – myoglobin: (CK-MB) 
 Cardiac tissue contains more of MB isoenzyme than skeletal muscle. 
Following a myocardial infarction there is a characteristic increase in serum CK 
activity. Although, measurement of activity of the MB isoenzyme was used in the 
past to detect myocardial damage, cardiac troponin measurement is now the 
preferred biomarker.  
It is detected in serum within 2-4 hours after onset of symptoms and peaks 
at 6- 9 hours. It remains elevated for 72 hours. 
Normal range: 5 – 25 IU/L.12, 13 
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1.11 Classification antihypertensive drugs:  
Table: 1 classification antihypertensive drugs8  
S. 
no 
Generic name 
Therapeutic 
dose (mg) 
Maximum 
dose (mg) 
Mechanism of 
action 
1. ACE inhibitors 
Captopril 
Enalapril 
Fosinopril 
Lisinopril 
Perindopril 
Quinapril 
Ramipril 
Trandopril 
 
12.5mg 
5mg 
10mg 
5mg 
4mg 
5mg 
2.5mg 
1mg 
 
450mg 
40mg 
80mg 
80mg 
16mg 
80mg 
20mg 
4mg 
Produce 
vasodialation effect 
2. ARBs 
Candesartan 
Eprosartan 
Irbesartan 
Losartan 
Olmesartan 
Telmisartan 
Valsartan 
 
8mg 
400mg 
150mg 
50mg 
20mg 
40mg 
80mg 
 
32mg 
800mg 
300mg 
100mg 
40mg 
80mg 
320mg 
Inhibit vascular 
smooth muscle 
contraction and 
produce vasodialation 
effect. 
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3. Calcium channel 
blockers 
Amlodipine 
Felodipine 
Lercanidipine 
Nefidipine 
Diltiazem 
Verapamil 
Clinidipine 
 
 
2.5mg 
5mg 
10mg 
10mg 
180mg 
80mg 
5mg 
 
 
10mg 
10mg 
30mg 
120mg 
540mg 
480mg 
20mg 
Blocks calcium 
channel and exerts 
vasodialation 
4. Thiazide diuretics 
Hydrochlorthiazide 
Chlorthalidone 
Indapamide 
 
25mg 
12.5mg 
1.5mg 
 
50mg 
100mg 
5mg 
Produce diuresis by 
inhibiting the 
reobsorption of 
sodium. 
5. β – blockers 
Atenolol 
Carvedilol 
Labetolol 
Metoprolol 
Nebivolol 
Oxprenolol 
Pindolol 
Propranolol 
 
25mg 
12.5mg 
100mg 
50mg 
5mg 
40mg 
10mg 
40mg 
 
100mg 
50mg 
400mg 
450mg 
40mg 
240mg 
60mg 
640mg 
Reduce cardiac 
output by decreasing 
arterial blood 
pressure 
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6. Others 
Potassium sparing 
diuretic 
Amiloride 
 
 
 
2.5mg 
 
 
 
10mg 
Reduce potassium 
and hydrogen 
secretion and their 
subsequent secretion 
7. Centrally acting alpha 
agonist 
Clonidine 
 
 
0.1mg 
 
 
2.4mg 
Reduce sympathetic 
outflow from the CNS 
and decreases 
peripheral resistance, 
heart rate, BP. 
8. Vasodialator 
Hydralazine 
Nicorandil 
 
50mg 
10mg 
 
300mg 
30mg 
 
Produce peripheral 
vasodialating effect. 
9. Aminoacid 
decarboxylase 
inhibitor 
Methyldopa 
Moxonidine 
 
 
 
250mg 
200mg 
 
 
 
3mg 
0.4mg 
 
 
 
Decrease plasma 
renin activity. 
 
10. 
 
Quinazoline derivative 
Prazosin 
 
0.5mg 
 
20mg 
 
Decrease total 
peripheral resistance. 
11. Aldosterone 
antagonist 
Spironolactone 
 
12.5mg 
 
100mg 
Increase the 
excretion of sodium, 
water and retains K.  
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During myocardial infarction, a level of cardiac markers is of crucial 
importance. In cardiac muscle they are tightly bound to the contractile apparatus 
and therefore plasma concentrations are extremely low. In myocardial injury, 
there is release of markers into the serum.  
Each markers can risk stratify patients with chest pain but their specificities 
for myocardial injury, release and clearance characteristics differ. However, 
treatment of hypertension patients with antihypertensive drugs implicates clinical 
and circulating improvement. 14, 15  
The use of anti hypertensive drug therapy has been shown to reduce the 
risk of stroke and CHD in long term randomized controlled trials. It also confirmed 
that the long-term survival advantages associated with improved adherence to 
antihypertensive therapy after acute myocardial infarction. 16        
So in this present study we have evaluated the effect of antihypertensive 
drugs on cardiac workload with the help of cardiac markers in post myocardial 
infarction patients.  
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2. LITERATURE REVIEW 
B. Singh et al., 2011 reviewed the usefulness of cardiac biomarkers like T-I, T-T, 
ck-mb, myoglobin, BNP, hs-CRP, myeloperoxidase, ischemia modified albumin 
in the diagnosis of ACS or AMI. Troponins are the prognostic indicators of MI and 
help to identify patients with increased risk. CK-MB assays have greater 
sensitivity in detecting smaller degree of myocardial damage and also for the 
diagnosis of reinfarction. Relative index improves specificity of CK-MB elevation 
for MI. myoglobin is the earliest marker but it lacks cardiac specificity. Hs-CRP, 
BNP, MPD, IMA is the emerging markers. Hence it is concluded that the cardiac 
markers are not only used for the diagnosis of AMI but also for risk stratification 
and prognostification of such patients. 13 
Kamble et al., 2002 studied the effect of antihypertensive drugs on cardiac 
enzymes in hypertension with myocardial infarction in NIDDM. To determine the 
effectiveness of antihypertensive drugs, a prospective study was conducted in 
hypertensive patients who had MI and DM diagnosed by WHO criteria were 
divided into group I (control), group II (enalapril) and group III (atenolol). Blood 
samples were collected after the onset of symptoms of MI and compared. It is 
concluded that the potentiality of enalapril is involved in cellular metabolism & 
repair process of the heart after MI. Hence CK-MB is considered to have greater 
predictive diagnostic accuracy than CK.14 
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Kristin newby et al., 2001 evaluated Bedside multimarker testing for risk 
stratification in chest pain units. This prospective study is designed to compare 
the ability of quantitative bedside measurement of CK-MB, myogloin & troponin I 
with different time to positivity characteristics to risk stratify patients with chest 
pain verses local laboratory results. It is concluded that rapid multi-marker 
analysis identifies positive patients earlier and provides better risk stratification 
for mortality than a single marker approach.15    
Giampiero Mazzaglia et. al., 2009 studied adherence to antihypertensive 
medications and cardiovascular morbidity among newly diagnosed hypertensive 
patients. The study concluded that long-term reduction of acute cardiovascular 
events associated with high adherence to antihypertensive treatment 
underscores its importance in assessments of the beneficial effects of evidence-
based therapies in the population. An effort focused on early antihypertensive 
treatment initiation and adherence is likely to provide major benefits.16 
Minuro Yoshiyama et al., 2005 studied Angiotensin converting enzyme inhibitor 
prevents left ventricular remodeling after MI in Angiotensin II type I receptor 
knockout mice. To elucidate the effect of ACE inhibitors that is not mediated by 
the AT1 receptor on LV remodeling. A study was conducted on mice in which MI 
was experimentally induced in WT & KO mice. Both control and test mice were 
treated with ace inhibitors & 4 weeks after MI, cardiac function was assessed by 
Doppler echocardiography and northern blot analysis. The study was concluded 
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that ace inhibitor prevents LV remodeling after MI by mechanisms other than 
inhibition of Angiotensin AT1 receptor mediated effects.
17 
Dirk weskrmann et. al., 2016 studied diagnosis of myocardial infarction using a 
high sensitivity troponin I, 1 hour algorithm. A prospective cohort study was 
conducted on troponin – I assay for the diagnosis of acute myocardial infarction. 
With application of low troponin I cut off value of 6ng/ml, 1 hr approach was 
comparable to a 3 hr approach & these two independent cohorts further validated 
the performance of this algorithm with high negative and positive predictive 
values. It results that patients with possible AMI can be triaged within 1hr after 
admission with no loss of safety which enables safe discharge or rapid treatment 
initiation after 1 hour.18  
Doson chua et al., 2011 evaluated Angiotensin converting enzyme inhibitors: An 
ACE in the hole for everyone. It is designed to study the use of ACE inhibitors to 
treat cardiovascular disorder. The use of ACEI’s in heart failure is well 
established and as proven to reduce mortality and morbidity. It is now routinely 
used in MI patients to reduce reinfarction, mortality risk and is combined with a 
diuretic for a secondary prevention in stroke patients. It also reduces the 
progression of diabetic nephropathy. It is evident that ACEI’s should be 
considered for all patients with diabetes or a history of cardiovascular diseases, 
except for those at low risk.19 
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Mehmet Akif cakar et al., 2012 analyzed the effect of admission creatinine 
levels on one - year mortality in acute myocardial infarction. A prospective study 
is conducted to find the relationship between admission creatinine level and one 
year mortality in patients with acute myocardial infarction. In this, patients were 
divided into 2 groups (normal & elevated groups). According to admission serum 
creatinine level which is measured within 12 hours of acute myocardial infarction 
and one year mortality rates were evaluated. This study concluded that the mildly 
elevated admission serum creatinine levels are markedly increased to one year 
mortality in patients with acute myocardial infarction.20 
Vinay rao et al., 2014 evaluated Risk factors for acute myocardial infarction in 
coastal region of India: A case – control study. A prospective case control study 
is done to assess the risk factors and their influence for AMI. A total of 100 cases 
of both age and gender matched controls were taken and their prevalence on risk 
factors like age, sex, diet, smoking, alcohol consumption, history of hypertension, 
history of diabetes mellitus & lipid profile were studied. This results that smoking 
and heavy drinking cessation, treatment of hypertension, reduction in blood 
glucose, correction of abnormal lipid profile either through use of statins or by 
dietary modifications may be important in preventing IHD in Asian Indians.21 
Pieter J de Kam et al., 2004 studied the revised role of ACEI’s after MI in the 
thrombolytic/ primary PCI era. In this, the process of left ventricular dilatation and 
the effects of ACEI’s after MI is studied. It has been generally accepted that 
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progression of LV dilatation is a major predictor of heart failure and death after 
MI. Also, attenuation of LV dilatation is the main mechanism by which ACEI’s 
exerts their beneficial effect. Reperfusion is obtained much more frequently and 
LV dilatation after MI has become less prevalent. Neverthless, ACEI’s proved 
effective in reducing cardiac morbidity and mortality. Therefore mechanisms 
other than attenuation of LV dilatation such as anti-atherosclerotic effects or 
plaque stabilization may explain the long term beneficial effects of ACEI’s after 
MI. 22    
Tobias reichlin et al., 2009 studied early diagnosis of myocardial infarction with 
sensitive cardiac troponin assays. A prospective, international, multicenter study 
is designed to examine the diagnostic performance of new sensitive cardiac 
troponin assays for the early diagnosis of acute myocardial infarction in 
emergency department. Cardiac troponin assays were performed in patients who 
presented with symptoms suggestive of AMI and their levels were determined in 
a blinded fashion with the use of 4 sensitive assays (Abbott – architect T-I, 
Roche high – sensitive T-T, Roche T-I & Siemens T-I ultra) and a standard assay 
(Roche T-I). The final diagnosis was adjudicated by 2 independent cardiologists. 
It is concluded that the diagnostic performance of sensitive cardiac troponin 
assays is excellent and these assays can substantially improve the early 
diagnosis of AMI, particularly in patients with a resent onset of chest pain.23 
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Asli tanindi et al., 2011 evaluated Troponin elevation in condition other than 
acute coronary syndrome. This study focuses on causes of troponin elevation 
other than ACS. Acute coronary syndrome comprise a large spectrum of clinical 
conditions ranging from unstable angina pectoris to acute ST- elevation MI. chest 
pain is usually the major symptom of atherosclerotic heart disease. However, it 
may be challenging to diagnose correctly in a ambiguous way that pain 
characterized by some patients. Cardiac troponins are sensitive and specific 
biomarkers used in the diagnosis of MI, they are the cornerstone for the 
diagnosis and risk assessment of MI. Troponin elevation indicates the presence, 
not the mechanism of MI. There are many clinical conditions other than MI that 
cause troponin elevation. Physicians should be aware of the wide spectrum of 
disease states that may result in elevation of troponin and have a clear 
understanding of the related pathophysiology to effectively make a differential 
diagnosis. 24 
Claudio picariello et al., 2011 this study focuses on hypertensive patients with 
acute coronary syndrome, to elucidate wheather the patients are at higher risk 
and deserve a tailored approach for management and followup. Arterial chronic 
hypertension is a well known cardiovascular risk factor or development of 
atherosclerosis. To explain the relation between hypertension and acute 
coronary syndrome, risk factors such as genetic risk, insulin resistance, 
sympathetic hyperactivity and vasoactive substances. Hypertension is associated 
with the development of atherosclerosis which in turn contributes to progression 
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of MI. Hence hypertensive patients with acute coronary syndrome are more likely 
to be older, female, non-white ethnicity and having higher prevalence of co-
morbidities data on the prognostic role of a preexisting hypertensive state on 
ACS patients are so far contrasting. 25 
Swee han lim et al., 2013 evaluated the use of cardiac markers in the diagnosis 
of acute coronary syndrome. Cardiac troponins are the most sensitive and 
specific biochemical marker of myocardial damage and an important diagnostic 
tool in the evaluation of ACS. However, high sensitivity troponins (hstn) have 
increased accuracy in the diagnosis of acute myocardial infarction and this 
combination may negate the need for other cardiac markers, but not the relative 
change. It has lower specificity in comparison with traditional troponin and its 
level may be elevated even in certain non-ACS settings. Given these pitfalls, the 
assessment of ACS most still is global, comprising clinical history, 
electrocardiogram changes, troponin change, and nuclear scan showing new 
loss of viable myocardium. Identification of patients with unstable patients without 
MI also remains a challenge, as the sensitivity of cardiac troponin in this area 
remains moderate to low. However, new cardiac markers such as copeptin, 
ischemia-modified albumin and heart type acid binding protein are still being 
studied and provide a window of hope in the diagnosis of unstable angina.26 
James A.de Lemos et al., 2006 studied the prevalence and determinants of 
CTnT elevation in a large, representative sample of the general population. The 
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dallas heart study is a population-based, multiethnic, probability sample of 
residents of dallas country, designed to study subclinical cardiovascular disease. 
In the general population, CTnT elevation is rare in subjects without CHF, LVH, 
CKD or DM suggesting that the upper limit of normal for the immunoassay should 
be <0.01µg/l. even minimally increased cardiac troponin T may represent 
subclinical cardiac injury and have important clinical implications, a hypothesis 
that should be tested in longitudinal outcome studies.27 
Andrea Milde hrn et al., 2016 evaluated the association between pain sensitivity 
and recognition of myocardial infarction. A cross – sectional study is conducted in 
participants who underwent the cold pressor test (a common experimental pain 
assay) and ECG. Participants with unrecognized myocardial infarction endured 
the cold pressor test significantly longer than participants with recognized 
myocardial infarction. The association between unrecognized MI and lower pain 
sensitivity was stronger in women than in men and statistically significant in 
women only, but interaction testing was not statistically significant (P = 0.14). It is 
concluded that persons who experience unrecognized MI have reduced pain 
sensitivity compared with persons who experience unrecognized MI have 
reduced pain sensitivity compared with persons who experience recognized MI. 
This may partially explain the lack of symptoms associated with unrecognized 
MI.28 
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Robert A. Byrne et al., 2016 a retrospective cohort study is conducted to assess 
the prognostic value of hs-cTnT and the influence of sex in patients with stable 
coronary artery disease undergoing elective percutaneous coronary intervention. 
Primary endpoint was all-cause mortality. Unadjusted hazard ratio (HR) in overall 
and sex – specific population and multivariable adjusted HR were calculated by 
using COX proportional hazard models. In elevated hs-CTnT levels, 99 percentile 
URL were observed at baseline, mortality is increased in patients with the sex – 
specific 99th percentile URL compound to those with normal hs-CTnT. It was 
concluded that in patients with stable coronary artery disease undergoing 
elective percutaneous coronary intervention, pre-procedural hsCTnT was a 
strong predictor of mortality in both men and women.29 
Sabesan mythili et al., 2015 studied the Diagnostic markers of acute myocardial 
infarction. This review is done to determine the various cardiac biomarkers 
released during the event of an AMI. AMI is a major cause of morbidity and 
mortality worldwide. The highest risk of fatality occurs within the initial hours of 
onset of AMI. Thus, early diagnosis of cardiac ischemia is critical for the effective 
management of patients with AMI. Improper diagnosis leads to inappropriate 
admission of patients without AMI and vice versa. In addition to clinical history, 
physical examination, accurate electrocardiogram finding & assessment of 
cardiac biomarkers have an important role in the early diagnosis o acute 
ischemia. It is concluded that cardiac biomarkers has become the frontline 
diagnostic tools for AMI and has greatly enabled the clinicians in the rapid 
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diagnosis and prompt treatment planning, thereby reducing the mortality rate to a 
great extent. 30  
Hafidh A. Al – Hadi et al., 2009 reviewed Cardiac markers in the early diagnosis 
and management of patients with acute coronary syndrome. This review is based 
on available markers of myocardial damage such as CK, CK-MB, CK-MB 
isoforms, heart type fatty acid-binding protein, myoglobin, CTnT, CTnI. Chest 
pain is the most frequent reason for patients seeking urgent medical attention. 
The current diagnostic and triage system based on clinical history & 
electrocardiograms are insufficient, this may results in misdiagnosis and delayed 
treatment. Hence this study concluded that the triage and management of 
patients with chest pain can be considerably improved by implementation of 
serial cardiac markers testing that identifies ACS in the very early stage of 
presentation.31  
Pedrinelli R et al., 2012 evaluated Hypertension and acute myocardial 
infarction: an overview. This review focuses on the hypertension which is a 
frequent finding in patients with acute myocardial infarction and its recurring 
association with female, DM, older age, less frequent smoking and more frequent 
vascular co-morbidities. Antecedent hypertension associates with higher rates of 
death and morbid events both during the early and long term course of AMI, 
particularly if complicated by left ventricular dysfunction and CHF. ACE inhibition 
and aldosterone antagonism exerts particular benefits in that higher risk 
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hypertensive subgroup. Higher systolic pressure at the onset of chest pain 
associates with lower mortality with in 1year from coronary occlusion whereas 
after hemodynamic stabilization, there is an inconsistent relationship with 
recurring coronary events in the long-term follow up. Hence antihypertensive 
treatment in post MI prevents ischemic relapses is uncertain. Excessive drop of 
diastolic pressure may jeopardize to new acute coronary events, to know about 
the underlying mechanisms it needs further evaluation. 32 
Alharbi F F.  et al., 2017 studied the risk of acute MI after discontinuation of anti-
hypertensive agents. A case control study. A nested case control cohort study is 
done to assess the association between discontinuation of different 
antihypertensive agents and the risk of AMI. In this study, patients who were 
hospitalized or their first AMI is considered as cases and controls were not 
hospitalized for AMI. Patients were divided into antihypertensive users and 
discontinuers as recent (≤ 90 days), intermediate term (91-180), long term (≥ 180 
days). The risk of AMI is significantly increased in discontinuers regardless of 
time compared to current users of drugs like β-blockers, CCBs, diuretics, ACEIs. 
This study concluded that the discontinuation of antihypertensive drugs increases 
the risk of AMI after >90 days of discontinuations. Hence it implies the 
importance of antihypertensive drug therapy to reduce the risk of AMI in patients 
with hypertension.33 
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Giovanni corrao et al., 2011 assessed whether antihypertensive Monotherapy 
or a combination antihypertensive therapy provides a greater CV protection in 
daily clinical practice. A case control study is carried out in patients aged 40 to 79 
years who were newly treated with antihypertensive drug. Cases were patients 
who experienced hospitalization for CV disease and controls were randomly 
selected. Logistic regression was used to model the CV risk associated with 
starting on and or continuing with combination therapy. It results that patients 
with combination therapy had 11% CV risk reduction with those starting on 
Monotherapy. Hence this study concluded that in daily life practice, a 
combination of antihypertensive drug is associated with great reduction of CV 
risk.34 
Garry tavern et al., 2016 assessed the effect of antihypertensive 
pharmacotherapy in preventing sudden cardiac death, non-fatal MI & fatal MI 
among hypertensive individuals, a randomized trial is done to select the patients. 
Comparison include one or more antihypertensive drug verses placebo or no 
treatment. The search methods include Cochrane register of studies online, Ovid 
MEDLINE, Ovid EMBASE, clinical trial.gov. This study concluded that 
antihypertensive drugs reduce incidence of fatal and non-fatal MI but they didn’t 
reduce the incidence of sudden death. Continued research is needed to 
determine the causes of sudden cardiac death.35    
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James J Dinicolantonia et al., 2015 studied β – blockers in hypertension, 
diabetes, heart failure, and acute myocardial infarction. This review focuses on β 
– blocker which is an essential class of cardiovascular medications for reducing 
morbidity and mortality in heart failure patients. This review discusses the 
cornerstone clinical trials that have tested β - blockers in the settings of HTN, 
DM, and stable CHD. This study mainly tested on the non-vasodialating β1 
selective blockers like atenolol, metoprolol and vasodialating β – blockers like 
carvidilol, nebivolol to determine the advantages over the other. This study 
concluded that carvidilol may have an advantage over the first generation β – 
blockers in patients with heart failure and acute myocardial infarction.36 
Muhammed firdaus et al., 2008 studied the prevention of cardiovascular events 
by treating hypertension in older adults. An evidence – based approach. A 
systematic pubmed search was conducted to look for evidence showing benefits 
of lowering BP in older hypertension adults. Lowering BP in these individuals will 
significantly reduce the risk of CAD, stroke and all cause mortality. From the trial 
evidence, it is found that a low dose diuretic should be considered as initial 
therapy for most hypertensive older adults. To prevent cardiovascular mortality 
and morbidity, therapy with >1 medication is often necessary to reduce BP in 
these patients.37 
Csaba farsang et al., 2011 evaluated the Indication and utilization of angiotensin 
receptor II blockers in patients at high cardiovascular risk. This review focuses on 
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ARBs which reduces the risk of cardiovascular events partly beyond that of blood 
pressure lowering effect. It has been shown ARBs are cardiovascularly protective 
and well tolerated. Although the eight available ARBs are all indicated for the 
treatment of hypertension, they have partly different pharmacology, 
pharmacokinetic and pharmacodynamic properties. Due to ARBs trials for the 
reduction of cardiovascular risk classification of differences in patients have led 
to their indications in different populations. It results that for patients at high 
cardiovascular risk, telmisartan is indicated. For patients with hypertension and 
specific risk factors losartan and irbesartan is effective. At highest cardiovascular 
risk with heart failure and left ventricular dysfunction candesartan, losartan and 
valsartan is indicated.38 
Giovanni corrao et al., 2017 evaluated the protective effects of antihypertensive 
treatment in patients aged 85 years or older. To assess whether in individuals 
aged 85years or older adherence to antihypertensive drugs reduces the risk of 
cardiovascular events. A case control study is done on patients aged 85 years or 
older who were newly treated with antihypertensive drugs. Cases were who 
experienced death/hospital discharge for stroke, MI or heart failure. Upto 5 
controls were randomly selected for each case. It concluded that the risk of CV 
morbidity in patients aged 85 years or more were reduced in adherence with 
antihypertensive drug therapy.39 
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Neil poulter et al., 2010 studied the effect of ARBs in reducing the CV risk. 
Evidence shows that ARBs are better tolerated compared to the other major drug 
classes in the treatment of hypertension patients. Overall, CV protective effects 
are similar between ACE inhibitor and ARBs but compared to other agents ARBs 
may offer better stroke protection. There is no robust evidence that ARBs are 
associated with significantly increased CV events, including MI compared to 
other anti-hypertensive agents.40  
Scott D. solomon et al., 2007 studied the Effect of antecedent hypertension and 
follow- up blood pressure on outcomes after high risk myocardial infarction. To 
assess the relationship between antecedent hypertension and outcomes and the 
association between elevated systolic BP >140mm Hg or low BP <100mm Hg in 
2 or 3 follow up visits during the first 6 months and subsequent CV events over a 
median 24.7 months of followup. Antecedent hypertension independently 
increased the risk of MI, HF, stroke, CV death or cardiac arrest. While low BP in 
the post MI period was associated with increased risk of adverse events. Patients 
with elevated BP were at significantly increasing the risk of stroke and combined 
cardiovascular events. Six months after a high-risk MI, elevated systolic BP a 
potentially modifiable risk factor is associated with an increased risk of 
subsequent stroke and CV events.41     
Noah jarari et al., 2016 studied a review on prescribing patterns of 
antihypertensive drugs. This review focuses on the antihypertensive medication 
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utilization, cost factors, adherence and guidelines in prescribing medications in 
different settings. It has been estimated that by 2025, 1.56 billion individuals will 
have hypertension. Due to the increase in cost and prevalence influences the 
prescribing patterns among physician and compliance to the treatment by the 
patient. The recent guidelines by the JNC8 recommended both CCB as well as 
ACE inhibitors as first line drugs. Combinations are generally used for effective 
long-term management and to treat co-morbid conditions. It concluded that in 
India, more systematic studies are required on the evaluations of prescribing 
patterns and guidelines based antihypertensive medication which can be tailored 
to suit the patient’s requirements.42 
Saad shafquat et al., 2007 evaluated Drug compliance after stroke and 
myocardial infarction: A comparative study. To assess whether compliance with 
prescribed medication after stroke or MI is similar in these 2 populations, a 
retrospective study is done on patients who had first-ever stroke or MI and 
compliance were assessed through telephonic survey. It results that compliance 
is highest with anti-hypertensive drugs followed by anti-platlet drugs and anti-lipid 
agents. It is concluded that compliance with prescribed regimens is appreciably 
lower after stroke than after MI.43 
Lori M. Dickerson et al., 2005 studied Management of hypertension in older 
persons. Antihypertensive therapy has been shown to reduce morbidity and 
mortality in older patients with elevated systolic or diastolic BP. This benefit 
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appears to persist in patients older than 80 years, but less than one-third of the 
older patients have adequate blood pressure control. Systolic BP is the most 
important predictor of CVD. Low dose thiazide diuretics remain first line therapy 
or older patients. β – Blockers, ACE inhibitors, ARB’s and CCB’s are the second 
line medications that should be selected based on co-morbidities and risk 
factors.44 
Shahid akbar  et  al., 2014 studied the current status of β – blockers use in the 
management of hypertension. This review focuses on the evolutionary changes 
of clinical uses of β – blockers in hypertension and advantages of newer 
additions to the group. β – Blockers are one of the most extensively used 
therapeutic drugs in both cardiac and non-cardiac ailments. Current uses of β – 
blockers in cardiovascular disease include ischemic heart diseases, 
hypertension, cardiac arrhythmias and heart failure. Other non- cardiac uses 
include glaucoma, migraine, situational anxiety, benign essential tremors and 
cardiac symptoms of thyrotoxicosis.45 
Robert J. Henning et al., 2015 reviewed recent advances in the diagnosis and 
treatment of myocardial infarction. The third universal definition of MI requires 
cardiac myocyte necrosis with an increased or decreased in CTn measurement 
during symptoms o myocardial ischemia, ECG ST-segment /T wave changes/left 
bundle branch block, development of pathological ECG Q waves, regional wall 
motion abnormality identified by an imaging technique, identification of 
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intracoronary thrombus by angiography. There have been significantly advances 
in adjunctive pharmacotherapy, procedural techniques and stent technology in 
the treatment of patients with MI. The routine use of antiplatelet agents and PCI 
reduces patient’s morbidity and mortality. Human bone marrow mononuclear 
cells have more advantages. These studies established that the 
intramyocardial/intracoronary administration of stent cells is safe. Additional 
clinical studies with cardiac stem cells are in progress.46 
Jennifer frank et al., 2008 studied the Management of hypertension using 
combination therapy. Most patients with hypertension require more than a single 
antihypertensive agent, particularly if they have co-morbid conditions. A JNC 
guideline recommends diuretic therapy as initial treatment for patients with 
hypertension. For patients with hypertension and diabetes mellitus β-blockers, 
ACE inhibitors and or CCBs and diuretic is recommended. For hypertension with 
coronary disease Diuretic, β-blockers, ACE inhibitors and or CCBs is 
recommended. For post MI, ACE inhibitors, β-blockers, aldosterone antagonist is 
recommended. ACE inhibitors and ARBs are recommended for patients with 
hypertension and CKD. Diuretic and ACE inhibitors are recommended for 
recurrent stroke prevention in patients with hypertension.47 
Bryam Williams et al., 2005 studied recent hypertension trials – implications 
and controversies.  These studies have provided definitive evidence of a 
treatment benefit and the weight and consistency of the clinical evidence has led 
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to uniformity in many aspects of treatment recommendations worldwide. 
However, controversies remain-in particular wheather specific class of drugs 
offer benefits for CVD prevention. Clinical trials are of short duration and there 
are more marked drug specific differences in intermediate cardiovascular 
structure, functions and metabolic end points. Although, blood pressure lowering 
is undoubtedly beneficial, the most effective way to go beyond BP is to add a 
statins.48 
Chantal bourgaut et al., 2001 studied Antihypertensives and MI risk: the 
modifying effect of history of drug use.  A case – control study is done to examine 
the controversy around MI risk in relation to antihypertensive agents by 
considering past drug history both as a confounder and as an effect modifier. In 
this, patients who had received ACEIs, CCBs / β-blockers and MI cases were 
identified and included in this study. Controls were matched to each case to 
account for duration and timing of follow up. It results that the use of CCBs & 
ACEIs Vs β-blockers increased the risk of MI. However, the risk for CCB use 
disappeared in patients who had already used these agents in the past. Hence 
this study concluded that past drug history can be both a confounder and an 
effect modifier.49 
Myron L. weisfeldt et al., 2007 studied advances in the prevention and 
treatment of CVD. Over the past 35years, usage adjusted mortality from CVD 
decline 50%. This marked reduction reflects advances in the prevention, 
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diagnosis and treatment of common CV conditions. They played a major role in 
the prevention of atherosclerosis and its consequences: heart attack, stroke and 
heart failure. Additionally, novel device-based therapies contribute to the decline 
in cardiac morbidity and mortality. It is hoped life style changes, early risk-factor 
screening and more efficacious drugs will strikingly reduce CVD in the future.50 
Norm R.C Campbell et al., 2009 the association between the changes in 
antihypertensive therapy with changes in hospitalization and death from major 
HTN related CVD in Canada. Using various databases, Canadian standardized 
yearly mortality and hospitalization rates per 1000 for stroke, HF and AMI were 
calculated for individuals aged ≥20 years and regressed against anti-
hypertensive prescription rates and changes were examined in a time series 
analysis. It results in significant reduction in rate of death and hospitalization rate 
with an increase in anti-hypertension prescriptions and that it coincides with the 
introduction of the Canadian hypertension education programme.51 
Mathias Abiodun Emolepae et al., 2017 evaluated CK-MB activity in 
uncomplicated hypertension and to determine whether sex difference exist in the 
activity of the enzyme. A prospective case controlled study is done on Nigerians 
with hypertension. Serum CK-MB, T-I and lipid profile were assayed using 
selectra pros chemistry analyser. The control groups of normotensive subjects 
were included. It results that serum CK-MB activity was higher in female than 
male hypertensive subjects. There was low or no difference in CK-MB and T-I 
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activity in normotensive subjects. Hence cardiac markers should e routinely done 
in the evaluation of hypertension subjects and sex specific consideration may be 
recognized in the management of the patients. 52 
Dorairaj Prabhakaran et al., 2016 studied cardiovascular diseases in India. A 
quarter of all mortality is attributable to CVD. IHD and stroke are the predominant 
causes for 80% of CVD deaths. In India, it is estimated that age standardized 
CVD death rate of 272 per 10 0000 population is higher than the global average 
of 235 per 100000 population. It is concluded that to address the socioeconomic 
and healthcare needs of the Indians, more resources need to be directed toward 
applying the excisting knowledge base to tackle the CVD epidemic in policy, 
programs, capacity building and research arenas.53     
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3. AIM AND OBJECTIVES 
Aim 
           To assess the level of cardiac markers during anti-hypertensive drug 
therapy in post myocardial infarction patients. 
Objectives 
 To evaluate the effect of anti-hypertensive drugs on cardiac 
workload in post myocardial infarction patients. 
 To assess changes in the level of cardiac markers in post - MI. 
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4. PLAN OF WORK 
The proposed study entitled “CLINICAL STUDY OF CARDIAC MARKERS IN 
POST MYOCARDIAL INFARCTION PATIENTS ON ANTIHYPERTENSIVE 
DRUG THERAPY” was planned and carried out in a tertiary care hospital as 
given below. 
Phase I 
 Identification of research problem and scope of the study 
 Literature survey 
 Preparation of study protocol 
 Obtaining approval from ethical committee 
Phase II 
 Design of structured proforma 
 Patient selection 
 Obtaining patient consent 
 Data retrieval from cardiology and medical record department 
Phase III 
 Data analysis 
 Report submission 
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5. METHODOLOGY 
5.1 STUDY DESIGN 
The study was a Prospective – Observational study. 
5.2 STUDY SITE 
The study was carried out in the department of cardiology at 
Vivekanandha Medical Care Hospital (VMCH), Elayampalayam, 
Tiruchengode. 
5.3 DURATION OF THE STUDY 
The study was conducted from July 2016 to June 2017 in the 
department of cardiology. 
5.4 INCLUSION CRITERIA 
 Age > 40 years 
 Gender – both male and female 
 Patients with post myocardial infarction 
 Patients with previous history on anti-hypertensive drug therapy. 
5.5 EXCLUSION CRITERIA 
 Pregnancy 
 Patients with multi-antihypertensive drug therapy 
 Patients with chronic renal failure 
 Hypothyroidism. 
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5.6 STUDY APPROVAL 
The study was approved (Ref.No:SVCP/IEC/JAN/2016/14) by 
institutional ethical committee of Vivekanandha Medical Care Hospital 
(Annexure – 1) 
5.7 STUDY POPULATION  
The study was conducted in Vivekanandha Medical Care Hospital, total 
250 patients who are having post MI and on antihypertensive drug therapy 
were screened and 108 patients was selected based on the following 
inclusion and exclusion criteria for further study. 
5.8 DATA SOURCE 
Data was collected from patient record, interviewing patient/ caretakers 
and from medical record department.  
5.9 STUDY METHOD 
 Patients with post myocardial infarction with history on antihypertensive 
therapy were selected for the study. Patient demographic details, previous 
medical history of MI and duration on antihypertensive treatment were 
collected from medical record department and the effectiveness of 
antihypertensive drug therapy on cardiac workload was evaluated with the 
help of cardiac markers. Patients were provided with information leaflet to 
improve understanding of disease management.  
 
  
Methodology 
 
Clinical study of cardiac markers in post myocardial infarction patients on Antihypertensive  
drug therapy  Page 39 
 
5.10 DATA ENTRY FORM 
 A specially designed data entry form was used in this study. It consists 
of following details name, age, sex, IP No, reason for admission, past medical  
history, past medication history, family history, social history, laboratory 
investigations, diagnosis and therapeutic chart was noted. (Annexure – 4) 
5.11 STATISTICAL ANALYSIS 
 Statistical analysis was done using graph pad Instat software, version 
3.01. Results were expressed as Mean ± SD. One way ANOVA followed by 
Tukey – Kramer multiple comparison test were used to analyze the statistical 
different of various groups. P <0.05 was considered significant.  
5.12 PATIENT INFORMATION LEAFLET 
  Patient information leaflet was prepared and distributed through 
cardiology department and its usefulness was assessed by using patient 
information leaflet usefulness assessment questionnaire (PILUAQ).  
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6. RESULTS 
6.1. Age distribution of myocardial infarction patients 
 Among the 108 MI patients 52 (48.1%) were in the age group of 40 – 60, 
62 (57.4%) were in the age group of 60 – 80 and 8 (7.4%) were in the age group 
of 80 -100. The age distribution showed that the age more than 60 are more 
prone to myocardial infarction.  
Table: 2 Age distribution of myocardial infarction patients 
S.no Age in years Number of patients Percentage (%) 
1. 40 - 60 52 48.1 
2. 60 -80 48 44.4 
3 80 - 100 8 7.4 
 
Figure: 2 Age distribution of myocardial infarction patients 
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6.2. Gender distribution of myocardial infarction patients 
 Among the 108 myocardial infarction patients 84 (77.7%) were males and 
24 (22.2 %) were females. The gender distribution showed that males are prone 
to myocardial infarction. 
Table: 3 Gender distribution of myocardial infarction patients 
S.no Gender Number of patients Percentage (%) 
1. Male 84 77.7% 
2. Female 24 22.2% 
 
Figure: 3 Gender distribution of myocardial infarction patients 
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6.3. BMI profile of myocardial infarction patients 
 Among the 108 myocardial infarction patients of our study all patients 
were normal and above normal. BMI (18.5 – 24.9). 
Table: 4 BMI profiles of myocardial infarction patients 
S.no Groups Sample size 
BMI (kg/m2) Mean ± 
SD 
1. Ramipril 12 23.85 ± 2.97 
2. Nebivolol 12 24.23 ± 3.26 
3. Nicorandil 12 22.85 ± 2.5 
4. Amlodipine 12 23.1 ± 4.91 
5. Atenolol 12 23.27± 2.39 
6. Carvedilol 12 24.65 ± 5.37 
7. Clinidipine 12 24.43 ± 2.54 
8. Metoprolol 12 25.41 ± 3.07 
9. Telmisartan 12 23.6 ± 3.66 
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6.4. Social habits: 
Smoking: 
 Among the 108 myocardial infarction patients 62 (57.4%) were smokers 
and 46 (42.5%) were non-smokers. It shows that smokers were more affected 
than non-smokers. 
Table: 5 Smoking 
S.no Smoking Number of patients Percentage (%) 
1. Smokers 62 57.4 % 
2. Non - smokers 46 42.5 % 
 
Figure: 4 Smoking 
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6.5. Alcoholic habits 
 Among the 108 myocardial infarction patients 66 (61.1%) were alcoholic 
and 42 (38.8%) were non – alcoholic. It shows that alcoholics were more affected 
than non alcoholics. 
Table: 6 Alcoholic habits 
S.no Alcoholic habits Number of patients Percentage (%) 
1. Alcoholic 66 61.1% 
2. Non – alcoholic 42 38.8% 
 
Figure: 5 Alcoholic habits 
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6.6. Duration of treatment  
Table: 7 Duration of antihypertensive drug treatment among the study 
population  
S.no Drug treatment 
Number  of 
patients 
Duration of treatment 
in years 
(mean ± SD) 
1. Ramipril 
 
12 9.58 ± 2.77 
 
2. Nicorandil 
 
12 5.1 ± 1.80 
 
3. Nebivolol 12 5.41 ± 1.20 
 
4. Amlodipine 12 7 ± 1.53 
 
5. Carvedilol 12 6 ± 1.70 
 
6. Clinidipine 12 5.75 ± 2.49 
 
7. Metoprolol 12 6.5 ±2.54 
 
8. Telmisartan 12 5.08 ± 2.61 
 
9. Atenolol 12 6.16 ± 2.36 
 
 
Figure: 6 Duration of antihypertensive drug treatment among the study 
population 
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6.7. TROPONIN – I PROFILE OF THE PATIENTS 
Table: 8 Effect of Ramipril vs Nicorandil on troponin- I profile of the patients 
S.no Treatment Mean ± SD 
1. Ramipril 2.65 ± 0.49 * * 
2. Nicorandil 8.48 ± 6.8 
   
 
Figure: 7 Effect of Ramipril vs Nicorandil on troponin- I profile of the 
patients 
Values are expressed in Mean ± SD * * P< 0.01 
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Table: 9 Effect of Nicorandil vs Amlodipine on troponin- I profile of the 
patients 
 
 
Figure: 8 Effect of Nicorandil vs Amlodipine on Troponin – I profile of the 
patients 
 Values are expressed in Mean ± SD * P< 0.05 
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1. Nicorandil 8.48 ± 6.89 
2. Amlodipine 3.98 ± 1.36* 
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Table: 10 Effect of different antihypertensive drugs on troponin – I profile of 
the patients 
S.no Treatment Mean ± SD 
1. Ramipril 2.65 ± 0.49 * * 
2. Nicorandil 8.48 ± 6.89 
3. Nebivolol 4.85 ± 3.17 
4. Amlodipine 3.98 ± 1.36 * 
5. Carvedilol 5.43 ± 1.87 
6. Clinidipine 6.43 ± 3.64 
7. Metoprolol 4.75 ± 1.24 
8. Telmisartan 4.43 ± 1.27 
9. Atenolol 6.12 ± 4.10 
Results 
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Table: 11 Compilation of mean difference in antihypertensive drugs on troponin – I profile 
 
s. 
no 
Drug names 
Mean difference of antihypertensive drugs  
Ramipril Nebivolol Amlodipine Telmisartan Clinidipine Metoprolol Atenolol carvedilol Nicorandil 
1. Ramipril        - 2.203    1.328    1.778    3.778    2.095 3.470     2.778    5.828 
2. Nebivolol  2.203 - 0.8750 0.4250 1.575 0.1083 1.267 0.5750 3.625 
3. Amlodipine 1.328 0.8750 -  0.4500 2.450 0.6833 2.142 1.450 4.500 
4. Telmisartan 1.778 0.4250 0.4500 - 2.000 0.3167 1.692 1.000 4.050 
5. Clinidipine  3.778  1.575 2.450 2.000 - 1.683 0.3083 1.000 2.050 
6. Metoprolol 2.095 0.1083 0.6833 0.3167 1.683 - 1.375 0.6833 3.733 
7. Atenolol 3.470 1.267 2.142 1.692 0.3083 1.375 - 0.6917 2.358 
8. Carvedilol    2.778 0.5750 1.450 1.000 1.000 0.6833 0.6917 - 3.050 
9. Nicorandil 5.828 3.625 4.500 4.050 2.050 3.733 2.358 3.050 - 
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Figure: 9 Effect of different antihypertensive drugs on troponin – I profile of the patients 
Data represents Mean ± Standard deviation 
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6.8. CK – MB profile of the patients 
Table: 12 Effect of Ramipril vs Nicorandil on CK – MB profile of the patients 
s. no Treatment Mean ± SD 
1. Ramipril 23.33 ± 19.97 * * 
2. Nicorandil 78.6 ± 45.7 
 
 
Figure: 10 Effect of Ramipril vs Nicorandil on CK – MB profile of the patients 
Values are expressed in Mean ± SD * * P< 0.01 
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Table: 13 Effect of different antihypertensive drugs on CK – MB profile of the 
patients 
S.no Treatment Mean ± SD 
1. Ramipril 23.33 ± 19.97 * * 
2. Nicorandil 78.66 ± 45.76 
3. Nebivolol 33.44 ± 28.16 
4. Amlodipine 34 ± 23.77 
5. Carvedilol 68.25 ± 49.09 
6. Clinidipine 45.72 ± 27.04 
7. Metoprolol 55 ± 46.21 
8. Telmisartan 44.33 ± 24.73 
9. Atenolol 61.69 ± 34.92 
 
 
 
Results 
 
Clinical study of cardiac markers in post myocardial infarction patients on Antihypertensive  
drug therapy  Page 53 
 
Table: 14 Compilation of mean difference in antihypertensive drug treatment on CK-MB profile 
 
s. 
no 
Drug names 
mean difference of antihypertensive drugs 
Ramipril Nebivolol Amlodipine Telmisartan Clinidipine Metoprolol Atenolol carvedilol Nicorandil 
1. Ramipril         - 10.108    10.667     21.000   22.392    31.667 38.358 44.917 55.333 
2. Nebivolol 10.108 - 0.5583 10.892 12.283  21.558 28.250 34.808 45.225 
3. Amlodipine 10.667 0.5583 - 10.333 11.725  21.000 27.692 34.250 44.667 
4. Telmisartan 21.000 10.892 10.333 - 1.392 10.667 17.358 23.917 34.333 
5. Clinidipine  22.392 12.283  11.725  1.392 - 9.275 15.967 22.525 32.942 
6. Metoprolol 31.667 21.558 21.000 10.667  9.275 - 6.672 13.250   23.667 
7. Atenolol  38.358 28.250  27.692 17.358 15.967 6.672 - 6.558 16.975 
8. Carvedilol  44.917 34.808  34.250 23.917 22.525 13.250 6.558 - 10.417 
9. Nicorandil  55.333 45.225 44.667 34.333 32.942  23.667 16.975 10.417 - 
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Figure: 11 Effect of different antihypertensive drugs on CK – MB profile of the patients 
Data represents Mean ± Standard deviation 
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Table: 15 Scores of patient information leaflet usefulness assessment 
questionnaire (PILUAQ) 56 
S.no questions 
Number 
answered 
Average 
1. Amount of information 
a) Too much 
b) Adequate 
c) Too little  
 
27 
115 
8 
 
18% 
76.6% 
5.3% 
2. Usefulness of the information 
a) Very useful 
b) Useful 
c) Not useful 
 
78 
61 
11 
 
52% 
40.6% 
7.3% 
3. Readability of the leaflet 
a) Very easy 
b) Easy 
c) Very difficult 
 
96 
52 
2 
 
64% 
34.6% 
1.3% 
4. Understandability of the 
content 
a) Very easy 
b) Easy 
c) Very difficult 
 
 
58 
84 
8 
 
 
38.6% 
56% 
5.3% 
5. Usefulness of the PIL 
a) Very useful 
b) Useful 
c) Not useful 
 
81 
57 
12 
 
54% 
38% 
8% 
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7. DISCUSSION 
Acute myocardial infarction is a major cause of death and disability. In 
India, premature mortality in terms of years of life lost because of CVD is 
increased by 59% from 23.2 million (1990) to 37 million (2010) and the age 
standardized CVD death rate of 272 per 10, 0000 populations is higher than the 
global average of 235 per 10,000 populations.53  
Approximately 15 million patients per year in the U.S and Europe present 
to the emergency department with chest pain or other symptoms suggestive of 
AMI. 
Rapid identification of acute MI is critical for the initiation of effective 
evidence-based medical treatment and management. 
ECG and measurement of cardiac troponin is the current diagnostic 
cornerstone for clinical assessment of acute myocardial infarction. ECG is often 
insufficient to diagnose AMI. 9  
In the past 30 years, improved immunochemical techniques have made it 
possible for rapid measurements of a variety of markers indicating myocardial cell 
death. 
It includes myoglobin, CK, CK-MB, Troponin etc. Several of these are 
serum proteins which has been found to be more sensitive in detecting acute 
myocardial infarction.12   
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Rise in level of these markers have been reported in hypertension with 
myocardial infarction.  
However, Treatment of hypertension patients with antihypertensive drugs 
implicates clinical and circulating improvement.14 
In this present study, the effect of antihypertensive drugs on cardiac 
workload was evaluated with the help of cardiac markers (Troponin – I, CK–MB) 
in post myocardial infarction patients. 
 We have included patients those who are diagnosed to have post 
myocardial infarction with a previous history on antihypertensive drugs like 
Ramipril, Nicorandil, Nebivolol, Amlodipine, Carvedilol, Clinidipine, Metoprolol, 
Telmisartan and Atenolol. We analyzed the effectiveness of these 
antihypertensive drugs on cardiac workload with the help of Troponin–I and CK-
MB of the patients was examined. 
DEMOGRAPHY 
The study comprised of 108 patients diagnosed as post myocardial 
infarction. Among the 108 post myocardial infarction patients 48.1% were in the 
age group of 40 – 60 years, 44.4% of patients were in the age group of 60 – 80 
years and 7.4% were in the age group of 80 – 90 years. (Table: 2, Figure: 2) 
In our study, among 108 patients males were accounted for 77.7% and 
females were accounted for 22.2%. (Table: 3, Figure: 3)  
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Sonia [53] et. al., resulted women experience their first acute myocardial 
infarction on average 9 years later than men. The result of this study was found 
to be similar with above study and indicated that males are more prone to 
myocardial infarction.  
In this study population majority of the patients were having normal body 
mass index (BMI - 18.5 – 24.9). (Table: 4). Among the 108 patients smokers 
were accounted for 57.4%, non-smokers were accounted for 42.5% and 61.1% 
were alcoholic and 38.8% were non-alcoholic. (Table: 5, 6, Figure: 4, 5) 
 Nasrin Hesabi[54] et.al., resulted effective risk factors on myocardial 
infarction such as age, sex, hypertension, diabetes and smoking which is similar 
to our study. 
A total 108 patients was included in the study and duration on 
antihypertensive therapy was recorded. The incidence rates for second – MI was 
resulted that Ramipril shows (9.58 ± 2.77), Nicorandil (5.1 ± 1.80), Nebivolol 
(5.41±1.20), amlodipine (7±1.53), carvedilol (6 ± 1.70), Clinidipine (5.75 ± 2.49), 
metoprolol (6.5 ± 2.54), telmisartan (5.08 ± 2.61) and atenolol (6.16 ± 2.36). 
(Table: 7, Figure: 6) 
Doson Chua [18]   et.  al., resulted that the routine use ACE inhibitors in MI 
patients reduce reinfarction and mortality risk.    
Our result coincides with Doson Chua et. al., that ACE inhibitors decrease 
the incidence of second MI.  
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Our study revealed that the Ramipril showed a greater control on troponin 
– I profile of the patients when compared to other drugs. In this, Ramipril (2.65 ± 
0.49) showed a significant control (P< 0.05) on troponin – I profile when 
compared to Nicorandil (8.48 ± 6.8) (Table: 8, Figure: 7) 
After Ramipril, Amlodipine showed a greater control on troponin – I profile 
of the patients when compared to other drugs. In this, amlodipine (3.98 ± 1.36) 
showed a significant control (P< 0.05) on troponin – I profile when compared to 
Nicorandil (8.48 ± 6.89). (Table: 9, Figure: 8) 
 Ramipril (2.65 ± 0.49) showed a significant control than amlodipine (3.98 
± 1.36) and showed a greater control than Telmisartan (4.43 ± 1.27), Metoprolol 
(4.75 ± 1.24), Nebivolol (4.85 ± 3.17), carvedilol (5.43 ± 1.87), Atenolol (6.12 ± 
4.10), Clinidipine (6.43 ± 3.64) and Nicorandil (8.48 ± 6.89). Among the nine 
drugs Ramipril showed a greater control in troponin – I profile of the patients. 
(Table: 10, Figure: 9) 
(Table: 11, 14) shows compilation of mean difference of antihypertensive 
drugs on troponin-I and CK-MB profile of the patients. 
In present study, Ramipril showed a greater control on CK – MB profile of 
the patients when compared to other drugs. In this, Ramipril (23.3 ± 19.97) 
showed a significant control (P< 0.01) on CK - MB profile when compared to 
Nicorandil (78.6 ± 45.7). (Table: 12, Figure: 10) 
 Ramipril (23.3 ± 19.97) showed a significant control than Nebivolol (33.44 
± 28.16) and showed a greater control than Amlodipine (34 ± 23.77), Telmisartan 
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(44.33 ± 24.73), clinidipine (45.72 ± 27.04), Metoprolol (55 ± 46.21), Atenolol 
(61.69 ± 34.92), Carvedilol (68.25 ± 49.09) and Nicorandil (78.66 ± 45.76).  
Among the nine drugs Ramipril showed a greater control in CK – MB profile of 
the patients. (Table: 13, Figure: 11) 
Kamble[14] et. al., says that the metabolic state of severely infarct 
myocardium is indicated by the increase of marker CK and CK – MB. They    
reported that Enalapril (ACE inhibitor) was found to have promising effect than 
atenolol.  
Our results coincides with the results of kamble et. al. that ACE inhibitors 
was found to have greater control in troponin - I and CK – MB profile in 
myocardial infarction patients.   
The developed patient information leaflet was assessed for usefulness 
using the PILUAQ which is a 5 item questionnaire. It results that 76.6% of the 
population found the amount of information provided in the leaflet was adequate. 
About 52% of respondents found information provided was very useful and 64% 
of respondents stated that the leaflet was very easy to read. About 56% 
respondents found that the content in the leaflet was easy to understand and 
54% found that the leaflet was very useful to them in understanding about their 
disease condition.  (Table: 15)    
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8. CONCLUSION 
In this study the effect of antihypertensive drugs like Ramipril, Nicorandil, 
Nebivolol, Amlodipine, Carvedilol, Clinidipine, Metoprolol, Telmisartan and 
Atenolol on cardiac workload with help of Troponin–I and CK – MB level in post 
myocardial infarction patients was evaluated.  
Our study revealed that Ramipril has significant control on troponin-I and 
CK-MB level in post MI, While Amlodipine showed a significant control only on 
troponin-I. 
Duration of antihypertensive drug treatment among the study population 
revealed that Ramipril decreases the incidence of second MI symptoms for 
longer duration and decrease the release of cardiac markers compared to other 
drugs. It may due to decrease in workload of heart by ACE inhibitors. 
Patient information leaflet was prepared and distributed through cardiology 
department to improve patients understanding of disease management and the 
developed leaflet was found to be very useful by the patients.     
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Annexure – 2 
(Informed Consent English)  
 
 
  
Vivekanandha Medical Care Hospital, Elayampalayam 
Institutional Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
(Strike off items that are not applicable) 
 
I / We (write name of the investigator(s) here),                                            am / are 
carrying out a study on the topic:                                                  as part of my / our 
research project being carried out under the aegis of the Department of:  
(Applicable to students only): My / our research guide is:  
 
The justification for this study is:  
The objectives of this study are:  
 
Primary Objective:  
Secondary Objective:  
Sample size:  
 
Study volunteers / participants are (specify population group & age group):  
Location:  
 
We request you to kindly cooperate with us in this study. We propose collect 
background information and other relevant details related to this study. We will be 
carrying out:  
 
Initial interview (specify approximate duration):  
  
Data collected will be stored for a period of     years. We will / will not use the data 
as part of another study. 
Health education sessions: Number of sessions: 1.Approximate duration of 
each session:  
 
Clinical examination (Specify details and purpose):  
 
Blood sample collection: Specify quantity of blood being drawn:   
 
No. of times it will be collected:  
 
Whether blood sample collection is part of routine procedure or for research 
(study) purpose:   
1. Routine procedure 2. Research purpose  
 
Specify purpose, discomfort likely to be felt and side effects, if any:  
 
Whether blood sample collected will be stored after study period: Yes / No, it 
will be destroyed 
 
Whether blood sample collected will be sold: Yes / No  
 
Whether blood sample collected will be shared with persons from another 
institution: Yes / No 
 
  
Medication given, if any, duration, side effects, purpose, benefits:  
 
Whether medication given is part of routine procedure: Yes / No (If not, state 
reasons for giving this medication) 
 
Whether alternatives are available for medication given: Yes / No (If not, state 
reasons for giving this particular medication) 
 
Final interview (specify approximate duration): NA If photograph is taken, 
purpose:  
 
Benefits from this study:   
 
Risks involved by participating in this study:  
 
How the results will be used:  
If you are uncomfortable in answering any of our questions during the course of 
the interview / biological sample collection, you have the right to withdraw from 
the interview / study at anytime. You have the freedom to withdraw from the 
study at any point of time. Kindly be assured that your refusal to participate or 
withdrawal at any stage, if you so decide, will not result in any form of compromise 
or discrimination in the services offered nor would it attract any penalty. You will 
continue to have access to the regular services offered to a patient. You will NOT 
be paid any remuneration for the time you spend with us for this interview / study. 
The information provided by you will be kept in strict confidence. Under no 
  
circumstances shall we reveal the identity of the respondent or their families to 
anyone. The information that we collect shall be used for approved research 
purposes only. You will be informed about any significant new findings - including 
adverse events, if any, – whether directly related to you or to other participants of 
this study, developed during the course of this research which may relate to your 
willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read 
to me, and has been explained to me by the investigator/s. Having understood the 
same, I hereby give my consent to them to interview me. I am affixing my 
signature / left thumb impression to indicate my consent and willingness to 
participate in this study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
Signature of the Interviewer with date:                                               Witness: 
     
  
 
 
 
 
 
Annexure– 3 
(Informed Consent Tamil)  
 
 
 Xg;Gjy; gbtk; 
Njjp: 
-----------------------------.Mfpa ehd;> VMCH kUj;Jtkidapy; ------------ Jiwapd; fPo;> -----------
---------------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------- vd;w jiyg;gpy; Ma;T Nkw;nfhs;s 
cs;Nsd;. 
 
vd; Ma;T topfhl;b: 
 
Ma;T Nkw;nfhs;tjw;fhd mbg;gil: 
 
 
Ma;tpd; Nehf;fk;: 
 
 
Ma;T Nkw;nfhs;Sk; ,lk;: 
 
Ma;tpd; gyd;fs;: 
 
 ,e;j Ma;tpy; fpilf;Fk; jfty;fs; -------------- tUlq;fs; ghJfhf;fg;gLk;.  ,it NtW ve;j 
Ma;tpw;Fk; gad;gLj;jg; gl khl;lhJ.  ve;j epiyapYk; cq;fisg; gw;wpa jfty;fs; ahUf;Fk; 
njhptpf;fg;gl khl;lhJ.  mit ,ufrpakhf itf;fg;gLk;. 
 ,e;j Ma;tpy; gq;Nfw;f xg;Gf;nfhs;Stjhy; ve;j tpjkhd gyDk; cq;fSf;Ff; fpilf;fhJ.  ve;j 
Neuj;jpy; Ntz;LkhdhYk; Ma;tpypUe;J tpyfpf; nfhs;Sk; chpik cq;fSf;F cz;L. 
 Ma;tpypUe;J tpyfpf;nfhs;tjhy; cq;fSf;F mspf;fg;gLk; rpfpr;irapy; ve;j tpj khw;wKk; 
,Uf;fhJ. 
 ,e;j Muha;r;rpf;fhf cq;fsplk; rpy Nfs;tpfs; Nfl;fg;gLk; / rpy ,uj;j khjphpfs; my;yJ jpR 
khjphpfs; vLf;fg;gLk;. 
 NkYk;> ,e;j Ma;tpy; gq;F nfhs;tJ cq;fs; nrhe;j tpUg;gk;.  ,jpy; ve;j tpjf; fl;lhaKk; ,y;iy.  
ePq;fs; tpUg;gg;gl;lhy;> ,e;j Ma;tpd; KbTfs; cq;fSf;Fj; njhpag;gLj;jg;gLk;. 
 
 
Ma;thshpd; ifnahg;gk; : 
 
Njjp    : 
 
Ma;Tf;Fl;gLgthpd; xg;Gjy;: 
 
 ehd; ,e;j Muha;r;rpapd; Nehf;fk; kw;Wk; mjd; gad;ghl;bidg; gw;wp njspthfTk;> 
tpsf;fkhfTk; njhpag;gLj;jg; gl;Ls;Nsd;.  ,e;j Muha;r;rpapy; gq;F nfhs;sTk;> ,e;j 
Muha;r;rpapd; kUj;Jt uPjpahd Fwpg;Gfis tUk; fhyj;jpYk; cgNahfg;gLj;jpf; nfhs;sTk; KO 
kdJld; rk;kjpf;fpNwd;. 
 
Ma;Tf;Fl;gLgthpd; ngah;> Kfthp : 
 
 
 
ifnahg;gk; : 
     Njjp  : 
  
 
 
 
 
 
 
Annexure 4 (Data Entry Form) 
 
 
 DATA ENTRY FORM 
Patient name:                                                   DOA:                         DOD:                                      
Age/sex:                                                           weight:                       height: 
Reason for admission: 
Diagnosis: 
Past medical history: 
Past medication history: 
Social/family history: 
 
Vital signs: 
S.no Date Temp BP PR RR 
      
 
Hematology: 
S.
no 
Lab 
parameter 
Values 
Normal 
range 
S.
no 
Lab 
parameter 
Values 
Normal 
range 
        
        
        
        
        
        
        
        
        
        
        
 
 
 S.no Cardiac markers Value Normal range 
    
    
    
    
 
Image study report: 
 
Medication chart: 
S.no 
Name of the drugs 
Dose Frequency 
Date of admission 
Brand name Generic name       
           
           
           
           
           
           
           
           
           
           
           
 
Discharge medication: 
  
 
 
 
Annexure 5 (Scores of patient 
information leaflet usefulness 
assessment questionnaire)  
 
 
 
Scores of Patient information leaflet (PIL) Usefulness Assessment 
Questionnaire in MI  
 
Questions                                          
 
1. Amount of information 
 
   a) Too much 
 
   b) Adequate 
 
   c) Too little 
 
2. Usefulness of the information 
  
    a) Very useful 
 
    b) Useful 
 
    c) Not useful 
 
3. Readability of the leaflet 
 
    a) Very easy 
  
    b) Easy  
 
    c) Very Difficult  
 
4. Understandability of the content 
 
    a) Very Easy 
 
    b) Easy 
 
    c) Very Difficult 
 
5. Usefulness of the PIL 
 
    a) Very useful 
 
    b) Useful 
 
    c) Not useful 
 
 
 
VIVEKANANDHA MEDICAL CARE HOSPITAL , Department of cardiology , Elayampalayam , Tiruchengode    
Myocardial infarction(MI) – what is it? 
An MI is a heart attack which happens when 
blood vessels that supply blood  to your heart 
are blocked. This can damage your heart and 
lead to an abnormal heart rhythm, heart failure 
or may become life-threatening. 
Signs and Symptoms of MI 
Chest pain 
 Heart burn 
Abdominal pain 
Nausea or vomiting 
Feeling weak 
Breathlessness 
Cold and sweaty 
Heart is beating very fast 
Sometimes no symptoms at all . 
DO’S 
 
 
 
 
  Take your medicines as  
     directed by your physician  
 
 
 
 
Quit smoking  and  alcohol 
 
Eat a heart healthy diet. 
Reduce salt intake 
Eat foods low in    
   cholesterol 
Limit saturated and trans  
    fats 
Eat  variety of fruits and  
    vegetables every day . 
 
Physical activity and 
exercise 
The goal is 30 to 60 min  
   a day, 5 to 7 days a week. 
Ask your health care  
   provider how  often &  
    how  long to exercise. 
Maintain a  
healthy weight 
 
 
Check and control your BP and blood sugar  
    level  regularly 
 Keep your cholesterol  levels under control  
 Manage your stress 
 Follow up with your physician as directed 
 Do exercise  regularly 
 
  
 
 
Avoid stressful work  
 Tell your doctor if you develop  
    cough, swelling , constipation  after   
     taking your medicine 
 
 DONT’S 
 
Don’t take OTC medicines                  
   without asking your health care  
   provider first  
Don’t stop taking medicines  
    without consulting your   
    physician . 
 
Swamy  Vivekanandha College of 
pharmacy 
Department of pharmacy practice 
Elayampalayam 
tpNtfhde;jh nkbf;fy; Nfh; `h];gpl;ly>; ,Uja kUj;Jt rpfpr;ir gphpT> visahk;ghisak;> jpUr;nrq;NfhL.
khuilg;G vd;why; vd;d?
,jaj;jpw;F ,uj;jk; nfhz;L tUk; jkdpapy; KOtJkhf 
milg;G Vw;gl;lNyh my;yJ ,uj;jk; te;J 
Nruhtpl;lNyh khuilg;G Vw;gLfpwJ.
mwpFwpfs;:
mjpf mOj;jj;Jld; 
neQ;rpy; typ
 tpah;j;jy
 neQ;nrhpr;ry;
 tapw;W typ
 Fkl;ly; kw;Wk; the;jp
 %r;R jpzwy;
 ,jak; kpf Ntfkhf Jbj;Jf;   
nfhz;bUj;jy;
nra;aNtz;bait
kUj;Jthpd;MNyhridg;b 
kUe;Jfiscl;nfhs;sTk;. 
Gifg;gpbj;jy; kw;Wk; kJ 
mUe;Jtij epWj;jp tplTk;.
MNuhf;fpakhd czit 
cl;nfhs;sTk;.
 cztpy; cg;gpd;             
msit Fiwj;Jf;    
nfhs;sTk;
 nfhOg;G rj;J mjpfk; 
cs;s czit jtph;f;f  
Ntz;Lk;.
 goq;fs; kw;Wk; 
fha;fwpfis mjpfk; 
cl;nfhs;s Ntz;Lk;.
 jpdKk; 30-60 epkplq;fs;
kw;Wk; thuj;jpw;F5-7ehl;fs; 
clw;gapw;rp nra;tij ,yf;fhf  
nfhs;sTk;.
 vt;tsT fhyk; kw;Wk; vt;tsT 
Kiw clw;gapw;rp nra;a 
Ntz;Lk; vd 
kUj;JtUld;MNyhrpf;fTk;.
 ,uj;j mOj;jk; kw;Wk; rh;f;fiuapd;
msit fl;Lg;ghl;by; itj;Jf;
nfhs;sTk;
 kd cisr;riy rkhspf;fTk;.
 cq;fs; kUj;Jtiuj; njhlh;G
nfhs;tij tof;fkhff; nfhs;sTk;.
 clw;gapw;rp nra;tij tof;fkhff;
nfhs;sTk;
nra;a$lhjit
 kUj;Jthpd; MNyhrid gb
ghpe;Jiuf;fg;gl;l kUe;Jfs;
vLj;Jf nfhs;tij jtph;g;gNjh
my;yJ Rakhf kUe;ij
cl;nfhs;tNjh $lhJ.
Rthkp tpNtfhde;jh kUe;jpay; 
fy;Y}hp
bghh;l;nkz;l; Mg; ghh;k]p   
g;uhrpl;b];,
jpUr;nrq;NfhL
 cly; viliaf;  
fl;Lg;ghl;by;   
itf;fTk;.
kd mOj;jk; jUk; Ntiyia jtph;f;fTk;.
 kUe;Jfs; cl;nfhz;l gpwF
,Uky;> tPf;fk; Nghd;w gpur;ridfs; 
te;jhy; kUj;Jtiu mZfTk.; 
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